Table 2. The apatinib monotherapy and evaluation.

Case	Apatinib and dosage	evaluation	PFS(months)	Advert effects
1	third-line, 500 mg/d	PR	7	hand-foot syndrome
2	second-line, 500 mg/d	SD	3.5	hypertension, aleucocytosis
3	third-line, 250 mg/d	SD	7	—
4	third-line, 250 mg/d	SD	2.5	—
5	third-line, 250 mg/d	SD	2	—
6	third-line, 250 mg/d	PR	10	hypertension
7	fourth-line, 250 mg/d	SD	3	hand-foot syndrome
8	third-line, 250 mg/d	SD	4.5	—
9	third-line, 250 mg/d	SD	1.5	hoarseness, hemoptysis
10	fourth-line, 250 mg/d	SD	5.5	hypertension
11	fourth-line, 250 mg/d	PD	-	—
12	third-line, 250 mg/d	PD	-	—
13	second-line, 500 mg/d	PD	-	thrombocytopenia, proteinuria
14	second-line, 250 mg/d	PD	-	—
15	second-line, 250 mg/d	PD	-	thrombocytopenia
16	third-line, 250 mg/d	PR	2	hypertension, proteinuria